Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era

Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era

Diffuse large B-cell lymphoma is an aggressive and biologically heterogeneous disease. R-CHOP is the standard first line therapy and cures more than 60% of patients. Salvage high-dose chemotherapy with autologous stem cell transplant remains the standard second-line treatment for relapsed or refract...

Full description

Bibliographic Details
Main Author: Eva González Barca
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Immunology
Subjects:
diffuse large B-cell lymphoma
relapsed/refractory
bispecific antibodies
non-Hodgkin lymphoma
post CART therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.909008/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.909008/full

Similar Items